We demonstrate a step-by-step protocol for the investigation of gene function in peritoneal tissue-resident macrophages in vivo, using lentiviral vectors.
Peritoneal tissue-resident macrophages have broad functions in the maintenance of homeostasis and are involved in pathologies within local and neighboring tissues. Their functions are dictated by microenvironmental cues; thus, it is essential to investigate their behavior in an in vivo physiological niche. Currently, specific peritoneal macrophage-targeting methodologies employ whole-mouse transgenic models. Here, a protocol for effective in vivo modulation of mRNA and small RNA species (e.g., microRNA) expression in peritoneal macrophages using lentivirus particles is described. Lentivirus preparations were made in HEK293T cells and purified on a single sucrose layer. In vivo validation of lentivirus effectivity following intraperitoneal injection revealed predominant infection of macrophages restricted to local tissue. Targeting of peritoneal macrophages was successful during homeostasis and thioglycolate-induced peritonitis. The limitations of the protocol, including low-level inflammation induced by intraperitoneal delivery of lentivirus and time restrictions for potential experiments, are discussed. Overall, this study presents a quick and accessible protocol for the rapid assessment of gene function in peritoneal macrophages in vivo.
Tissue-resident macrophages (Mφ) are a heterogeneous population of phagocytic immune cells that sense and respond to invading pathogens1,2. In addition, they play an essential role in tissue development, remodeling, and maintaining homeostasis1,3. Many tissue Mφ derive from yolk sac progenitors during embryogenesis and persist in the tissue throughout the life4,5. The phenotype and functions of these cells are dictated by collaborative and hierarchical interactions of specific transcription factors and the local microenvironment6,7,8,9. A growing understanding of this dependency increases the need for effective in vivo methods for gene manipulation of Mφ within their physiologically relevant niche.
Lentiviral vectors are a frequently employed tool for the manipulation of nucleic acids in specific cell populations in vivo10,11,12, particularly due to their ability to infect both dividing and non-dividing cells and to stably integrate into host genome13,14. Over the last two decades, lentivirus delivery technology has been optimized, and alternative envelopes and synthetic promoters have been investigated to increase lineage-specific targeting8,15. Owing to its broad cell tropism, vesicular stomatitis virus envelop glycoprotein (VSV-G)16,17 has become the "gold-standard" envelope used in lentivirus technology.
In this protocol18, VSV-G pseudotyped lentiviral particles are employed to demonstrate targeted and effective delivery of short hairpin RNA (shRNA) and microRNA (miR) to mouse peritoneal Mφ (pMφ) in vivo, at steady state19. Transgene expression was driven by the spleen focus forming virus (SFFV) promoter. Productive infection of cells was defined by expression of lentivirus-derived enhanced green fluorescent protein (GFP). Utilization of this approach allowed easy readout for in vivo lentivirus experiments to define the optimal dose and the experimental timeframe. Finally, in vivo lentiviral challenge of mice during thioglycolate-induced inflammation revealed the natural propensity for selective pMφ infection.
All animal work was conducted in accordance with Institutional and UK Home Office guidelines.
NOTE: All in vivo studies with lentivirus should be performed according to local and national guidelines on the ethical use of animals in research, as well as adhering to all regulations associated with the use of category II infectious materials. Animal welfare should also be monitored in accordance with local regulations. In this step of the protocol, extreme care needs to be taken when working with lentiviral particles and sharps.
1. Preparation of HEK293T cells for transfection
NOTE: Perform these steps under a sterile tissue culture biological safety cabinet.
2. Transfection of HEK293T cells using non-liposomal lipid transfection reagent
3. Collection of lentiviral particles
4. Purification of lentivirus
5. Titration of lentivirus production in Jurkat T cells
6. In vivo lentivirus infection of tissue-resident peritoneal macrophages
7. Collection of peritoneal cells from lentivirus-infected mouse
CAUTION: For collections within 72 h post lentivirus injection, follow institutional category II biological safety rules. Bedding and holding cage where infected animals were kept in the first 72 h post lentivirus injection must be decontaminated according to institutional category II biological safety rules.
8. Peritoneal cell staining and analysis
9. Extraction of cells from organs
When followed fully and correctly, this protocol yields a total of 1.5 mL of high-quality lentivirus stock per single preparation, sufficient for twelve in vivo injections at the optimal volume determined in this study18. The success of the transfection can be evaluated early in the protocol. Healthy and confluent HEK293T cells should display, if present in the plasmids, an easily detectable marker signal (e.g., GFP used in this study) after 48 h post plasmid transfection (Figure 1A). The low intensity of the signal, excessive cell detachment, and low confluency at early steps of the protocol could indicate cell death and will result in a low yield of the lentivirus preparation. Some of the cell detachment prior to optional collection II (step 3.5.1.) is visible and expected.
Three plasmids are used in this protocol for generation of lentivirus particles: pCMV-ΔR8.91 packaging plasmid encoding structural HIV-1 protein (Gag), accessory proteins Tat and Rev, and reverse transcriptase polymerase (Pol)22; pMD2.G encoding VSV-G envelop under CMV promoter13; and pHR'SIN-cPPT-SEW plasmid (encoding enhanced GFP marker)19 modified accordingly for the expression of shRNA or microRNA.
Lentivirus preparations are titrated in the Jurkat T cell line due to their high infectivity23. Successful lentivirus preparation will achieve an infection rate of over 95% with a dose as small as 5 µL (Figure 2A). The mean fluorescent intensity of the infected cells continues to increase with the higher doses (Figure 2B,C). If required, viral titers can be measured using real-time PCR of integrated viral components, e.g., the SFFV promoter, which correlated linearly with percentage GFP-expressing cells and logarithmically with GFP MFI (Figure 2D). Depending on the construct, particularly those with a large insert24, some lentivirus preparations can display reduced infectivity in Jurkat T cells, as demonstrated for Cre-GFP construct used in this study (Figure 2E,F). In such a case, multiple preparations of lentivirus particles could be combined and resuspended in 1 mL. We recommend validating immune responses to those preparations in vivo prior to experimentation. Naturally, lentivirus preparations with alternative entry receptors to VSV-G used here might display different infection efficiency in the Jurkat T cell line, depending on the receptor expression on the cells. Cell lines used for the titration should be selected so they express the receptor used by the lentivirus particles to enter the cells and would preferentially lack or have very low expression of the restriction factors25.
Successful production of lentiviral particles is further evidenced by infection of pMφ (defined as CD11b+ F4/80+ and Tim4+ population)18 (Figure 3A). We determined that intraperitoneal injection of 100 µL lentivirus preparation (in total volume of 200 µL of serum-free media) yields the highest percentage and intensity of the GFP signal in these cells (Figure 3B,C). Injections of higher doses (150 µL and 200 µL of lentivirus preparation) had no beneficial impact on GFP expression in the pMφ. Time course experiments at 4 h, 3 days, 7 days, and 14 days post intraperitoneal (i.p) injection with 100 µL lentivirus revealed a significant percentage of GFP-expressing resident pMφ at days 3 and 7, followed by the disappearance of the infected population at day 14 (Figure 3D, E). Interestingly, GFP-expressing pMφ mostly disappears by day 14 post-infection, due in part to immune recognition of the GFP marker. Indeed, lentivirus experiments with GFP marker in T-Reg selective, Foxp3-DTR-eGFP mice prevent rejection of infected resident pMφ until at least day 21 (Figure 3F). For lentivirus preparations with diminished effectiveness in Jurkat cells, a higher amount would be required to achieve the expected infection rate in vivo. However, as demonstrated with Cre-GFP lentivirus preparation, depending on the construct design, even a dose of 300 µL at 7 days post i.p injection might yield a poor outcome (Figure 3G). We have previously demonstrated successful use of this protocol for overexpression and knockdown of genes in vivo in mouse pMφ, including lentiviral shRNA-mediated Map3k8 and Gata6 knockdown, and Gata6 overexpression19. Here, we show that this protocol can be also successfully employed for overexpression of murine microRNA 146b (mmu-miR-146b) and for knockdown of intercellular adhesion molecule 1 (ICAM1, CD54) using lentiviral derived shRNA in resident pMφ (Figure 3H,I).
Infection of primary cells, such as macrophages, requires higher lentivirus input, presumably due to the presence of restriction factors in these cells. Restriction factors are natural protective mechanisms of cells that interfere with viruses' life-cycle steps, such as reverse transcription or integration, leading to inhibition of gene expression from the constructs.
Further in vivo validation of the protocol demonstrated no effect of the i.p lentivirus delivery on peritoneal immune cell viability (Figure 4A) and indicated distinct infectivity of resident pMφ subpopulations (defined by the expression of CD73 and Tim4 markers) (Figure 4B,C). Importantly, productive lentivirus infection was limited to resident Mφ at the site of injection as evidenced by lack of significant GFP expression in mesenteric lymph node (mLN), lung, liver, or spleen Mφ after 7 days post-challenge (Figure 4D). Considering that in many cases, genetic targeting of Mφ is required to be performed under inflammatory conditions, we investigated the effectiveness of this protocol in mice challenged intraperitoneally with 0.1 mL of 4% thioglycolate. Thioglycolate injection triggers an influx of inflammatory monocyte-derived Mφ and monocytic cells that can be divided into 5 distinct populations (Figure 4E). Flow cytometry analysis revealed a refractory phenotype of monocytic-like cells (Ly6Chi populations 1 and 2) to lentivirus infection, in line with previous findings in human cells26. In contrast, resident Mφ and monocytes (groups 3-5) remained most susceptible to infection (Figure 4F).
Detailed flow cytometric analysis detected GFP expression predominantly in resident peritoneal Mφ and major histocompatibility complex (MHC) class II+ resident pMφ (MHCII+ F4/80+ Tim4+) (up to 60 % at day 3 after injection) (Figure 5A). Little to no GFP signal was detected in other peritoneal cell populations, including bone marrow-derived peritoneal Mφs/DCs (MHCII+, CD11b+, CD11c+), B cells (CD19+), T cells (CD3+), mast cells (CD11b–, FcεR1+), eosinophils (Siglec-F+), NK cells (CD19–, NK1.1+) and neutrophils (Ly6G+) (Figure 5A,B). GFP expression longevity (Figure 5C) in all populations followed this of resident peritoneal Mφ (Figure 1D). A transient increase in neutrophil frequency was recorded after 4 h post i.p injection of 100 µL (in a total volume of 200 µL of serum-free media) of lentivirus (Figure 5D), indicating early mild inflammation present in challenged animals. Finally, resident pMφ experienced a major drop in the frequency between days 7 and 14 post-infection (Figure 5E), suggesting the best experimental window between days 3 and 7 post-injection.
Figure 1: Lentivirus production in HEK293T cells. (A) Representative immunofluorescence pictures of HEK293T cells 48h after successful transfection (fluorescent microscope [488 nm excitation peak, 510 nm emission peak], 20x magnification, scale bar = 400 µm). (B) Photograph of ultracentrifuge conical tube containing a layer of 20% sucrose (bottom, clear) and a layer of medium collected from transfected HEK293T cells (top, red). (C) Photograph of correct insertion of the conical ultracentrifuge in the bucket, including adaptor. (D) Photographs showing correct and incorrect balancing of the ultracentrifuge rotor. (E) Photograph of the optimal setup of the Cat II cabinet and materials for in vivo injections for a right-handed individual. This figure has been modified with permission from Ipseiz N et al.18. Please click here to view a larger version of this figure.
Figure 2: Lentivirus titration in Jurkat T cells. (A) Representative flow cytometric analysis of Jurkat T cells 72 h after infection with increasing doses of lentivirus containing a GFP plasmid showing the percentage of GFP+ cells (GFP+), (B) mean fluorescence intensity (MFI) of GFP+ cells and (C) a representative histogram of GFP expression. (D) Scatter plot showing MFI (left Y) and the percentage of cells infected with a GFP-expressing lentivirus (right Y) versus the copy number of virus detected per pg of DNA (x-axis). (E) A representative histogram of Jurkat T cell infection with suboptimal Cre-GFP lentivirus (Cre-GFP LV) preparation and control GFP lentivirus (GFP LV) and (F) summary data showing the percentage of Cre-GFP lentivirus infected Jurkat T cells (GFP+). This figure has been modified with permission from Ipseiz N et al.18. Please click here to view a larger version of this figure.
Figure 3: Infection efficiency of the resident pMФ. (A) Gating strategy of resident pMφ (CD11b+, Tim4+, F4/80+) and Tim4–, F4/80+ cells. Cells were gated on singlets, followed by CD11b+. (B) Representative dot plots, and (C) a summary of infection frequency (% GFP+ cells) and intensity (MFI) of GFP+ cells isolated 3 days after in vivo infection with different amounts of GFP lentivirus preparation. (D) Representative dot plot, and (E) a summary of infection frequency (% GFP+ cells) and intensity (MFI) of GFP+ cells isolated at different time points after in vivo infection with 100 µL of lentivirus in a total volume of 200 µL of serum-free media medium. (F) A summary of cell numbers at days 7, 14, and 21 after intra-peritoneal delivery of GFP-expressing lentivirus in Foxp3-DTR-eGFP mice showing the number of GFP-expressing pMφ and inflammatory macrophages and dendritic cells (InfMØs/DCs [F480low]). (n= 1-2 per group). (G) Representative dot plot of suboptimal in vivo infection of Gata6-KOmye 19 resident pMφ with 300 µL of Cre-GFP lentivirus 7 days post i.p injection. (H) RT-qPCR quantification of mmu-miR-146b-5p expression of resident peritoneal Mφ challenged in vivo with 100 µL lentivirus encoding murine microRNA-146b (miR-146b) or control (C). Resident pMφ (white circles) and Tim4–, F4/80+ cells (grey circles). (I) A representative dot plot of successful downregulation of ICAM1 on pMφ in female 129S6 mice, 7 days after i.p injection of lentivirus containing targeting shRNA. Control shRNA is shown. The overlay shows isotype control. Data expressed as mean ± SEM, n≥2 mice. This figure has been modified with permission from Ipseiz N et al.18. Please click here to view a larger version of this figure.
Figure 4: Infection efficiency of the resident pMφ subpopulations. (A) Percentage of total single cells and resident Mφ viable 7 days after 100 µL serum-free media (-) or GFP lentivirus (+) i.p injection. (B) Gating strategy showing four major populations of pMφ found in vivo: CD73+Tim4+, CD73–Tim4–, CD73+Tim4–, CD73–Tim4+, and (C) corresponding infection frequency (% GFP+ cells) and intensity (MFI of GFP+ cells) of these populations. (D) Percentage of GFP+ cells in multiple organs 7 days after 100 µL lentivirus i.p injection. Abbreviations: mLN, mesenteric lymph node. (E) Mice were injected i.p with 0.1 mL of 4% thioglycolate for 5 days followed by i.p injection with lentivirus. Gating strategy of pMφ and monocytes post 3 days after lentivirus i.p injection. (F) Infection frequency, MFI, and cell number analysis of GFP+ monocytes (Ly6C+) and Mφ (Ly6C–). Data expressed as mean ± SEM, n≥3 mice. This figure has been modified with permission from Ipseiz N et al.18. Please click here to view a larger version of this figure.
Figure 5: Impact of lentivirus injection on peritoneal inflammation. Mice were injected in vivo i.p with GFP expressing lentivirus. (A) Infection frequency of cell populations in the peritoneal cavity following various amounts of lentivirus injections (50 µL, 100 µL, 150 µL, or 200 µL). (B) Intensity of GFP expression in productively infected cell populations at 7 days post i.p injection. (C) Infection frequency of cell populations in the peritoneal cavity at various time points after i.p injection. (D) and (E) Percentage of cells at various time points after i.p injection. All lentivirus injections were performed with the same total volume of 200 µL completed by serum-free media medium. Unless specified otherwise, 100 µL lentivirus dose was used. Control mice ("C") received 200 µL of neat serum-free media medium. Data expressed as mean ± SEM, n≥3 mice. This figure has been modified with permission from Ipseiz N et al.18. Please click here to view a larger version of this figure.
Antibody target | Fluorophore | Clone | Dilution used | final concentration [μg/mL] |
HIV-1 Core antigen | RD1 | FH190-1-1 | 1/100 | 1 |
I-A/I-E | PerCpCy5.5 | M5/114.15.2 | 1/400 | 0.5 |
Ly6G | PerCpCy5.5 | 1A8 | 1/400 | 0.5 |
CD3e | PerCpCy5.5 | 17A2 | 1/200 | 1 |
CD3e | PE/Cy7 | 500A2 | 1/400 | 0.5 |
CD11c | PE/Cy7 | N418 | 1/800 | 0.25 |
CD11c | BV605 | N418 | 1/400 | 0.5 |
CD226 | AF647 | 10 E 5 | 1/400 | 1.25 |
Tim4 | AF647 | RTM4-54 | 1/600 | 0.83 |
CD4 | APC | GK1.5 | 1/400 | 0.5 |
CD11b | AF700 | M1/70 | 1/700 | 0.71 |
CD11b | PerCpCy5.5 | M1/70 | 1/400 | 0.5 |
F4/80 | Pacific Blue | BM8 | 1/700 | 0.71 |
F4/80 | BV605 | BM8 | 1/400 | 0.25 |
F4/80 | BV711 | BM8 | 1/400 | 0.5 |
CD73 | eFluor450 | TY/11.8 | 1/400 | 2.5 |
CD19 | V450 | 1D3 | 1/400 | 0.5 |
CD19 | APC | 1D3 | 1/400 | 0.5 |
CD8a | eFluor450 | 53-6.7 | 1/400 | 0.5 |
SiglecF | BV421 | E50-2440 | 1/400 | 0.5 |
NK1.1 | APC/Cy7 | PK136 | 1/400 | 0.5 |
FceR1 | eFluor450 | MAR-1 | 1/400 | 0.5 |
ICAM1 | PE | 1A29 | 1/100 | 2 |
Rat IgG1, κ isotype control | PE | 1/100 | 2 |
Table 1: List of antibodies
Tissue-resident macrophages perform a range of homeostatic and inflammatory tissue-specific functions1,2 dictated by their physiological environment6,7,8,9. In this protocol, an effective method18 for manipulation of peritoneal resident macrophages in vivo using lentivirus particles was introduced to investigate macrophage function in their biological microenvironment.
It is essential for the success of the protocol to use healthy HEK293T cells. It is the best practice to defrost the cells at least a week prior to the start of this protocol to ensure cell recovery and good numbers. Cells should be seeded in an appropriate volume of medium one day before planned transfection and should reach about 80% confluency on the day of transfection. Under- or over-confluent cell preparations will result in reduced lentivirus yield. We recommend transfecting HEK293T cells with the transfection reagent according to the manufacturer's instructions for the best results. Essential steps of the transfection include appropriate mixing of the plasmids and reagents and dropwise addition of the mix directly to the HEK293T cell monolayer. Calcium phosphate transfection of HEK293T cells27,28 could be employed in this protocol. However, the user should be aware that the effectiveness of this method can vary, and it can result in diminished transfection efficiency.
Safety precautions should be considered in the protocol from the day of HEK293T cell transfection. These include working in a category II safety cabinet, wearing double gloves when handling contaminated material, and appropriate bleaching of the contaminated material (with decontamination solution, for example, 2,000 ppm bleach solution) for minimum 4 h. Users should refer to their institutional regulations regarding work with category II pathogens and waste.
In this protocol, the lentivirus preparation is first purified using a 0.45 µm filter to remove HEK293T cell debris. The use of smaller filters (0.22 µm) and cellulose ester membranes should be avoided as it will result in the loss of lentivirus particles. It is recommended to use low protein binding polyether sulfone or polyvinylidene fluoride filters29. The second purification step is performed on the single 20% sucrose layer in an ultracentrifuge to remove remaining impurities, which is particularly important for the consequent in vivo administration of the lentivirus preparation. In the institutions where an ultracentrifuge is not available, others30 have described sucrose-based lentivirus purification using a standard laboratory centrifuge. This could be implemented in this protocol as an alternative. Lentivirus preparation is titrated in Jurkat T cells on the expression of the marker signal (e.g., GFP used in this protocol). For constructs without markers, physical lentivirus particles could be evaluated by quantification of HIV-1 p24gag protein by ELISA kit31, flow cytometry analysis of HIV-1 core antigen18, or measurement of the changes to the targeted gene (preferentially using the methods allowing measurement of changes in individual cells, e.g., flow cytometry or microscopy). If titration of the control and lentivirus differ significantly in Jurkat T cells, the volumes used for the in vivo studies can be adjusted to reach the most comparable infection between lentivirus preparations.
The major limitation of the protocol is the observed disappearance of GFP+ resident peritoneal Mφ within 14 days of i.p lentivirus injection. For long-term studies, mouse lines with stable genetic alteration in a specific cell type or tissues should be considered32. For example, as peritoneal macrophages do not express Foxp3 (a T-Reg protein), we utilized Foxp3-DTR-eGFP mice33 and confirmed that expression of GFP is maintained in peritoneal Mφ at 21 days post-infection (Figure 3F). However, it is important to note that the lentiviruses contain other foreign components, and this extension in the persistence of infected cells in the Foxp3-DTR-GFP mice may not be permanent. An additional weakness of this method is a low level of inflammation that can be observed in the peritoneal cavity following lentivirus injection, as witnessed by influx of neutrophils at 4 h post injection (Figure 5D), which may mean repeated infections would accelerate the inflammation-associated loss of GFP-expressing resident peritoneal Mφ. Although, we have not detected type I interferons (IFNs) in the peritoneal cavity, VSV-G pseudotyped lentivirus particles were previously demonstrated to induce some of the IFN-stimulated genes in human Mφ in the absence of detectable IFNs34. This should be considered when using this protocol for experiments investigating antiviral immune responses. The occurrence of acute and sustained inflammation after i.p injection of lentivirus preparation might indicate contamination of the preparation.
Areas of troubleshooting include: 1) for low lentivirus titer, ensure the health of HEK293T cells and effective transfection (e.g., marker expression, if present, in HEK293T cells). If the infection rate remains low, consider the size of the construct. Constructs with larger inserts or more complex secondary structures can affect the final lentivirus titer and infectivity24. Therefore, each construct should be tested independently and in parallel to its respective control vector; 2) If a high amount of the lentivirus is required, it is recommended to prepare multiple T175 flasks of HEK293T cells and to scale up the production accordingly. To avoid variation of the lentivirus preparations, it is the best practice to merge the final collections prior to aliquoting and storage. For such larger production, plasmids mix (section 2) should be prepared in 50 mL tubes to ensure effective mixing of the components.
Despite its broad tropism, VSV-G pseudotyped lentiviral particles predominantly target tissue macrophages as demonstrated previously for alveolar35, and here18 for pMФ when administered by the respective routes. Alterations to the envelope on lentivirus particles can, in some cases, result in diminished transduction of macrophages in vivo36 and are unnecessary for this protocol. Compared to other viral approaches for in vivo gene manipulation in macrophages (reviewed in37), the use of lentiviral vectors offers stable integration of the transgene in tissue macrophages35, efficient transgene expression, and the largest vector size limit (approximately 8 Kb).
Peritoneal Mφ play an important role in the prevention, onset, progression, and resolution of various diseases, including abdominal cancers, pancreatitis, and peritonitis38. This protocol describes an effective tool for gene modification in murine pMφ, allowing investigation of the biological processes behind these pathologies within a physiologically relevant microenvironment. While lentiviral vectors themselves are becoming a tool of interest for clinical interventions39, due to the origin from the immunodeficiency virus and a stable genome integration, the safety concerns impede their therapeutic implementation. Further understanding of the macrophage responses to lentiviral gene modulation could advance the application of this highly effective tool in a clinical setting.
The authors have nothing to disclose.
This research was funded, in whole or in part, by the Wellcome Trust Investigator Award [107964/Z/15/Z]. P.R.T is also supported by the UK Dementia Research Institute. M.A.C is supported by the Biotechnology and Biological Sciences Research Council Discovery Fellowship (BB/T009543/1). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. L.C.D is a lecturer at Swansea University and an honorary research fellow at Cardiff University. This work is supported by work carried out by Ipseiz et al. 202018.
0.05% Trypsin-EDTA (1x) (Trypsin 500 mg/L or 0.02 mM) | Thermo Fisher Scientific | 25300054 | |
0.22 μm sterile millex GP filter | Merck | SLGS033SS | |
0.45 μm sterile millex GP filter | Merck | SLHP033RS | |
0.5 mL U-100 insulin syringe with needle, 0.33 mm x 12.7 mm (29 G) | BD | 324892 | |
1 Litre Sharps Container | N/A | N/A | |
2.4G2 antibody (TruStain FcX anti-mouse CD16/32) | Biolegend | 101320 | |
40 μm strainer | Thermo Fisher Scientific | 22363547 | |
AimV medium (research grade), AlbuMax Supplement | Thermo Fisher Scientific | 31035025 | |
Blocking buffer | prepared in house | ||
Brewer thioglycolate medium | Sigma-Aldrich | B2551 | 4% stock solution prepared in water, autoclaved and kept frozen. |
CD11b | Biolegend | 101222 | Refer to Table 1 for the dilution and concentration |
CD11b | BD | 550993 | Refer to Table 1 for the dilution and concentration |
CD11c | Biolegend | 117317 | Refer to Table 1 for the dilution and concentration |
CD11c | Biolegend | 117333 | Refer to Table 1 for the dilution and concentration |
CD19 | BD | 560375 | Refer to Table 1 for the dilution and concentration |
CD19 | Biolegend | 152410 | Refer to Table 1 for the dilution and concentration |
CD226 | Biolegend | 128808 | Refer to Table 1 for the dilution and concentration |
CD3e | BD | 560527 | Refer to Table 1 for the dilution and concentration |
CD3e | Biolegend | 152313 | Refer to Table 1 for the dilution and concentration |
CD4 | Biolegend | 100412 | Refer to Table 1 for the dilution and concentration |
CD73 | eBioscience | 16-0731-82 | Refer to Table 1 for the dilution and concentration |
CD8a | eBioscience | 48-0081-82 | Refer to Table 1 for the dilution and concentration |
Cell culture flask (T175 fask, 175 cm2, 550 mL) | Greiner Bio One | 658175 | |
Centrifuge tubes, conical bottom tubes 25 mm x 89 mm | Beckman Coulter | 358126 | |
Centrifuges | Beckman Coulter | Ultracentrifuge and TC centrifuge | |
Collagenase type IV | Sigma-Aldrich | C5138 | |
Conical centrifuge tubes (15 mL and 50 mL) | Greiner Bio One | 11512303 & 11849650 | |
Cryotubes | Greiner Bio One | 123277 | or cryotubes |
DMEM medium (1x) + 4.5g/L D-glucose, 400 µM L-glutamine | Thermo Fisher Scientific | 41965-062 | |
Dnase I | Sigma-Aldrich | 11284932001 | |
Effectene transfection reagent | Qiagen | 301425 | |
F4/80 | Biolegend | 123123 | Refer to Table 1 for the dilution and concentration |
F4/80 | Biolegend | 123133 | Refer to Table 1 for the dilution and concentration |
F4/80 | Biolegend | 123147 | Refer to Table 1 for the dilution and concentration |
FceR1 | eBioscience | 48-5898-80 | Refer to Table 1 for the dilution and concentration |
Fetal calf serum (FCS) | Thermo Fisher Scientific | 10270-106 | heat inactivated for 30 min at 56 °C and sterile filtered through 0.22 μm filter |
Flow cytometer | Thermo Fisher Scientific | Attune NxT | |
Flow cytometry (FACS) buffer | prepared in house | ||
Fluorescent tissue culture microscope | Thermo Fisher Scientific | EVOS FL | |
Forceps | N/A | N/A | User preference |
Hank's balanced salt solution (HBSS) | Gibco, Life Technologies | 14175-053 | |
HEK293T cell line | grown for at least a week prior transfection. Mycoplasma free | ||
HIV-1 Core antigen | Beckman Coulter | 6604667 | |
Hyaluronidase | Sigma-Aldrich | H3506 | |
Hydrex surgical scrub, chlorhexiding gluconate 4% w/v skin cleanser | Ecolab | 3037170 | |
I-A/I-E | Biolegend | 107625 | Refer to Table 1 for the dilution and concentration |
ICAM1 | Becton Dickinson | 554970 | Refer to Table 1 for the dilution and concentration |
Jurkat T cell line | grown for at least a week prior use. Mycoplasma free | ||
LIVE/DEAD fixable near-IR dead cell stain kit | Thermo Fisher Scientific | L34975 | |
Ly6G | Biolegend | 127615 | Refer to Table 1 for the dilution and concentration |
Mice | here used C57BL/6 females, aged 8-12 weeks (Charles Rivers), unless specified differently | ||
Microcapillary pipettes (volume range 0.5-1,000 μL) | Fisher Scientific & Starlab | 11963466 & 11943466 & 11973466 & S1111-3700 | |
NK1.1 | Biolegend | 108724 | Refer to Table 1 for the dilution and concentration |
Paraformaldehyde | Sigma-Aldrich | P6148-500G | prepared to 2% w/v in PBS |
pCMV-ΔR8.91 packaging plasmid | Zuffrey, R., et al. 1997 | encodes Gag-Pol HIV protein driven by cytomegalovirus promoter. Ampicilin resistance. | |
Penicillin/Streptomycin (100x, 10,000 U/mL) | Thermo Fisher Scientific | 15140122 | |
Petri dish | Greiner Bio One | 664160 | |
pHR'SIN-cPPT-SEW plasmid | Rosas, M. et al. 2014 | modified for shRNA and miR expression studies. Encodes EGFP marker downstream SFFV promoter and upstream of the Woodchuck hepatitiv virus enhancer. Ampicilin resistance. | |
pMD2.G plasmid | Naldini, L. et al. 1996 | encodes vesicular stomatis virus g-glycoprotein (VSV-G) envelope. Ampicilin resistance. | |
Rat IgG1, κ isotype control | Becton Dickinson | 550617 | Refer to Table 1 for the dilution and concentration |
Rat serum | Sigma-Aldrich | R9759-10ML | |
Red blood ACK lysis buffer | prepared in house | ||
RPMI 1640 medium (1x) + 400 uM L-glutamine | Thermo Fisher Scientific | 21875-091 | |
Saponin | Sigma-Aldrich | S4521 | |
SiglecF | BD | 562681 | Refer to Table 1 for the dilution and concentration |
Sodium hypochlorite Tablets (bleach, 2,000 ppm) | Guest Medical | H8818 | |
Sterile 24-well cell culture plate | Greiner Bio One | 662160 | |
Sterile Dulbecco's PBS (DPBS) (1x) Mg++ and Ca2+ – free | Thermo Fisher Scientific | 14190144 | |
Sterile EDTA | Thermo Fisher Scientific | 15575020 | |
Sterile VWR disposable transfer pipets (23.0 mL, 30 cm) | VWR | 612-4515 | |
Sucrose | Thermo Fisher Scientific | 15503022 | |
surgical scissors | N/A | N/A | User preference |
Syringes (50 mL and 1 0mL) | Fisher Scientific | 10084450 & 768160 | |
Tim4 | Biolegend | 130007 | Refer to Table 1 for the dilution and concentration |
U-bottom 96-well cell culture plate | Greiner Bio One | 650180 |